Easy To Use Patents Search & Patent Lawyer Directory

At Patents you can conduct a Patent Search, File a Patent Application, find a Patent Attorney, or search available technology through our Patent Exchange. Patents are available using simple keyword or date criteria. If you are looking to hire a patent attorney, you've come to the right place. Protect your idea and hire a patent lawyer.

Searching:





Search by keyword, patent number, inventor, assignee, city or state:




Patent # Description
2016/0347849 ANTIBODIES AGAINST OX40 AND USES THEREOF
Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications,...
2016/0347848 THERAPEUTIC COMBINATIONS AND METHODS FOR TREATING NEOPLASIA
Provided herein are methods of treating a solid tumor comprising administering an effective amount of MEDI4736 or an antigen-binding fragment thereof,...
2016/0347847 Anti-OX40 Antibodies and Methods of Use Thereof
The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific...
2016/0347846 FUSION PROTEINS FOR MODULATING REGULATORY AND EFFECTOR T CELLS
The present invention provides fusion proteins that act on the glucocorticoid-induced TNFR family-related gene (GITR) and OX40 signaling pathway. In certain...
2016/0347845 POLYNUCLEOTIDES ENCODING AN ACTRIIB ANTIBODY
The disclosure provides, among other aspects, neutralizing antibodies and portions thereof that bind to ActRIIB and uses for same.
2016/0347844 AGENTS THAT MODULATE RGMb-NEOGENIN-BMP SIGNALING AND METHODS OF USE THEREOF
The present invention relates to compositions and methods for the modulation RGMb-Neogenin-BMP signaling.
2016/0347843 ISOFORM SPECIFIC SOLUBLE FMS-LIKE TYROSINE KINASE (SFLT) BINDING AGENTS AND USES THEREOF
Aspects of the present disclosure relate to binding agents (e.g., antibodies and antigen binding fragments) that bind soluble fms-like tyrosine kinase 1...
2016/0347842 PROTEIN BINDING DOMAINS STABILIZING FUNCTIONAL CONFORMATIONAL STATES OF GPCRS AND USES THEREOF
The present invention relates to the field of GPCR structure biology and signaling. In particular, the present invention relates to protein binding domains...
2016/0347841 NEW MONOCLONAL ANTIBODIES AGAINST THE RECEPTOR DEC-205 OF CHICKEN DENTRITIC CELLS
The invention relates to the production and the characterisation of new murine monoclonal antibodies that recognize the domain CTD-2 (SEQ ID NO: 1) of the cell...
2016/0347840 Prostate Specific Membrane Antigen (PSMA) Bispecific Binding Agents and Uses Thereof
Provided herein are isolated CD3.times.PSMA-bispecific antigen-binding molecules or bispecific antigen-binding fragment thereof wherein a FN3 domain...
2016/0347839 Antibodies Comprising Chimeric Constant Domains
Antibodies, antigen-binding proteins and Fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence...
2016/0347838 EFFECTOR-DEFICIENT ANTI-CD32A ANTIBODIES
Effector-deficient anti-CD32a monoclonal antibodies are encompassed, as are method and uses for treating CD32a-mediated diseases and disorders, including,...
2016/0347837 OPTIMIZED Fc VARIANTS AND METHODS FOR THEIR GENERATION
The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
2016/0347836 TREATMENT OF HODGKIN'S LYMPHOMA USING AN ANTI-PD-1 ANTIBODY
This disclosure provides methods for treating Hodgkin's lymphoma in a subject comprising administering to the subject an anti-Programmed Death-1 (PD-1)...
2016/0347835 METHOD OF INHIBITING METASTASIS OF CANCER CELLS AND MODULATING AUTOIMMUNE DISEASES USING GAL-3BP-Fc FUSION PROTEIN
A tGal-3BP-Fc fusion protein, a pharmaceutical composition, an isolated nucleic acid, a recombinant expression vector, and a method of inhibiting, decreasing,...
2016/0347834 Anti-Podoplanin Antibody
Object of the present invention is to provide various anti-podoplanin antibodies useful as a drug or reagent. The present invention provides an anti-podoplanin...
2016/0347833 ANTIBODY PROCESS
The present invention provides a method for removing unwanted antibody aggregates, and/or antibody dimers, and/or antibody pre-monomers.
2016/0347832 ANTI-TRANSTHYRETIN HUMANIZED ANTIBODY
A humanized antibody which comprises a complementarity determining region of an H chain consisting of the amino acid sequence as shown in SEQ ID NOs: 1 to 3...
2016/0347831 CAMELID SINGLE-DOMAIN ANTIBODY DIRECTED AGAINST AMYLOID BETA AND METHODS FOR PRODUCING CONJUGATES THEREOF
The present invention relates to variable domain of a camelid heavy-chain antibodies directed to amyloid .beta. and conjugates thereof. The present invention...
2016/0347830 IMMUNOGLOBULIN AGAINST THE ANTHRAX TOXIN
The present invention relates to a class-G immunoglobulin against the anthrax toxin protective antigen (PA), or one of the fragments of same, comprising at...
2016/0347829 Compositions containing antimicrobial IgY antibodies, for treatment and prevention of disorders and diseases...
The present invention encompasses methods and compositions for inhibiting, treating, and preventing dental diseases in human and non-human animals,...
2016/0347828 Non-HIV Vaccine Antigen from the Vaginal Microbiota Capable of Inducing a Mucosal Neutralizing Protective...
A new non-HIV vaccine antigen from Mycoplasma sp. permease capable of inducing a mucosal neutralizing protective antibody response against HIV infection, a...
2016/0347827 ANTIBODIES AGAINST F GLYCOPROTEIN OF HENDRA AND NIPAH VIRUSES
The present invention relates to antibodies or antibody fragments that bind, neutralize, and/or inhibit Hendra or Nipah virus. The invention provides...
2016/0347826 AFFINITY LIGANDS AND METHODS RELATING THERETO
Affinity ligands useful for mild elution affinity chromatography, including affinity ligands specific for immunoglobulins M, A, and E, are disclosed as are...
2016/0347825 OPTIMIZED Fc VARIANTS AND METHODS FOR THEIR GENERATION
The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
2016/0347824 SELECTIVE REDUCTION OF PROTEINS
The present invention provides a method for making uncapped cysteine protein preparations, including uncapped engineered cysteine antibody preparations. The...
2016/0347823 A CHROMATOGRAPHY SYSTEM AND METHOD FOR CAPTURING A BIOPOLYMER
The present invention relates to a chromatography system (20) wherein the chromatography system comprises an eluting system (10) and a capturing system (11)...
2016/0347822 ADENO-ASSOCIATED VIRUS MEDIATED DELIVERY OF C1EI AS A THERAPY FOR ANGIOEDEMA
This invention is directed to a vector which comprises a promoter operably linked to a nucleic acid sequence encoding the human C1 esterase inhibitor or Factor...
2016/0347821 P97 FUSION PROTEINS
Provided are p97 (melanotransferrin)-trastuzumab fusion proteins and related methods of use thereof, for instance, to facilitate delivery of trastuzumab across...
2016/0347820 METHOD OF MAKING COLLAGEN POWDER FROM MARINE CARTILAGE AND SKIN
A method of making hydrolyzed marine Type II collagen includes the mixing of marine cartilage, water, an enzyme and a protease enzyme for an extended period of...
2016/0347819 PROCESS FOR PRODUCING AND PURIFYING FACTOR VIII AND ITS DERIVATIVES
Disclosed is a method for producing proteins having factor VIII procoagulant activity in serum-free medium by in vitro culturing of mammalian cells, wherein...
2016/0347818 Compositions and Methods for Immunomodulation in an Organism
The present invention relates to a therapeutic polypeptide and methods for its creation and use for modulating an immune response in a host organism in need...
2016/0347817 FGFR-FC Fusion Proteins and the Use Thereof
The present invention belongs to the field of biotechnology and relates to the treatment of diseases, especially the treatment of FGF overexpression-related...
2016/0347816 POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF FOR TREATMENT OF IMMUNE RELATED DISORDERS AND CANCER
This invention relates to LY6G6F, VSIG10, TMEM25 and LSR proteins, which are suitable targets for immunotherapy, treatment of cancer, infectious disorders,...
2016/0347815 PEPTIDE MIMOTOPES OF CLAUDIN 18.2 AND USES THEREOF
The present invention provides molecules that mimic antigenic determinants of the integral transmembrane protein claudin 18.2 (CLDN18.2). These molecules...
2016/0347814 VSTM5 POLYPEPTIDES AND USES THEREOF AS A DRUG FOR TREATMENT OF CANCER, INFECTIOUS DISEASES AND IMMUNE RELATED...
This invention relates to VSTM5 proteins, soluble molecules and fusions thereof which are suitable targets for drug development and for treatment of immune...
2016/0347813 GLUCAGON ANALOGUES
The invention provides glucagon analogue peptides and their use for promoting weight loss or preventing weight gain, and the treatment of obesity or excess...
2016/0347812 Novel Glucagon Analogues
The present invention relates to novel glucagon peptides, to the use of said glucagon peptides in therapy, to methods of treatment comprising administration of...
2016/0347811 PHARMACEUTICAL PREPARATION
Preparations including recombinant FSH (rFSH).
2016/0347810 COMPOSITIONS AND METHODS FOR TREATING ACUTE AND CHRONIC PAIN BY LOCAL ANTAGONISM OF CGRP RECEPTORS, OR...
The present invention provides compositions, and methods for local administration of certain peptides or combination with certain small molecules that produce...
2016/0347809 HOMOGENEOUS PREPARATIONS OF IL-31
Homogeneous preparations of human and murine IL-31 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding...
2016/0347808 NOVEL PEPTIDES AND COMBINATION OF PEPTIDES AND SCAFFOLDS THEREOF FOR USE IN IMMUNOTHERAPY AGAINST COLORECTAL...
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates...
2016/0347807 TARGETING P53 AND ITS DNA-BINDING DOMAIN
Disclosed are peptides comprising a full length p53 or a partial p53 and a mitochondrial targeting signal. Also disclosed are nucleic acids that encode...
2016/0347806 OLIGOMERIZATION DOMAIN OF P53 TO BYPASS THE DOMINANT-NEGATIVE EFFECT OF MUTANT
Disclosed are peptides comprising a partial p53 peptide and a mutated Bcr coiled-coil domain. Also disclosed are nucleic acid sequences capable of encoding a...
2016/0347805 BIOMARKER FOR HUMAN EYES AND METHOD THEREOF
The present invention provides a biomarker for detecting and diagnosing polypoidal choroidal vasculopathy (PCV) of human eyes, including levels of...
2016/0347804 TAU PEPTIDES, ANTI-TAU ANTIBODIES, AND METHODS OF USE THEREOF
Isolated tau peptides, and compositions comprising the peptides are disclosed. Further provided are antibodies specific for an isolated tau peptide. Methods of...
2016/0347803 NUCLEOTIDE SEQUENCE AND PHARMACEUTICAL COMPOSITION BASED THEREON WITH PROLONGED VEGF TRANSGENE EXPRESSION
A nucleic acid or transgene comprising a modified VEGF 3'-untranslated region (3'-UTR) polynucleotide sequence and a polynucleotide sequence encoding a...
2016/0347802 INTERACTION OF DRAXIN AND Y-NETRINS
This invention relates to extracellular protein-protein interactions and their possible therapeutic uses. More particularly, this invention describes the...
2016/0347801 PEPTIDES DERIVED FROM NCAPG2 AND THEIR USE
NCAPG2, a component of condensin complex II, protein and novel peptides derived from the protein are provided. The peptide may include a fragment of the NCAPG2...
2016/0347800 SHORT PEPTIDE-BASED THERAPEUTIC AGENT AND MEDICINAL COMPOSITION INCLUDING THE SAME FOR INHIBITING ACTIVITIES OF...
The present invention relates to a short peptide-based therapeutic agent and a medicinal composition including the same for inhibiting activities of cancer...
← Previous | 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 | Next →

File A Patent Application

  • Protect your idea -- Don't let someone else file first. Learn more.

  • 3 Easy Steps -- Complete Form, application Review, and File. See our process.

  • Attorney Review -- Have your application reviewed by a Patent Attorney. See what's included.